

HALOPERIDOL DECANOATE- haloperidol decanoate injection

Zydis Pharmaceuticals USA Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HALOPERIDOL DECANOATE INJECTION safely and effectively.

See full prescribing information for HALOPERIDOL DECANOATE INJECTION

HALOPERIDOL DECANOATE injection, for intramuscular use

Initial U.S. Approval: 1986

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Haloperidol decanoate is not approved for the treatment of patients with dementia-related psychosis (5.1).

----- INDICATIONS AND USAGE -----

Haloperidol decanoate is a typical antipsychotic indicated for the treatment of schizophrenia in adults who were previously taking a stable dosage of an immediate-release oral haloperidol product (1).

----- DOSAGE AND ADMINISTRATION -----

- Administer haloperidol decanoate by deep intramuscular injection every 4 weeks by a healthcare provider. **Do not administer intravenously** (2.1).
- For the recommended dosage, including the first recommended dose and the maintenance dosage, see the Dosage and Administration section (2.1).
- If schizophrenia symptoms worsen during dosage modification of haloperidol decanoate, consider administering an immediate-release oral haloperidol product in addition to haloperidol decanoate therapy (2.2).

----- DOSAGE FORMS AND STRENGTHS -----

Injection:

- Haloperidol 50 mg/mL (present as haloperidol decanoate) in single-dose and multiple-dose vials (3).
- Haloperidol 100 mg/mL (present as haloperidol decanoate) in single-dose and multiple-dose vials (3).

----- CONTRAINDICATIONS -----

- Severe toxic central nervous system depression or comatose states from any cause (4).
- Known hypersensitivity to haloperidol or any components of haloperidol decanoate injection (4).
- Parkinson's disease (4, 5.7, 6.1).
- Dementia with Lewy bodies (4, 5.7).

----- WARNINGS AND PRECAUTIONS -----

- *Sudden Death, Torsades de Pointes (TdP) and QTc Interval Prolongation:* Avoid use of haloperidol decanoate in patients who are at risk of developing TdP. Avoid concomitant use of haloperidol decanoate with drugs that may increase risk of QTc interval prolongation or increase haloperidol exposure. Obtain ECG and serum electrolytes at baseline and during treatment as clinically indicated (5.2).
- *Tachycardia and Hypotension:* Monitor orthostatic vital signs (5.3).
- *Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis:* Use with caution in patients with schizophrenia who have risk factors for cerebrovascular adverse reactions (5.4).
- *Tardive Dyskinesia:* Discontinue treatment if clinically appropriate (5.5).
- *Neuroleptic Malignant Syndrome (NMS):* Immediately discontinue and monitor closely (5.6).
- *Seizures:* Haloperidol decanoate is generally not recommended in patients receiving antiseizure drugs or who have a history of seizures or EEG abnormalities. If clinically indicated, maintain patients taking haloperidol decanoate on adequate antiseizure therapy (5.8).
- *Potential for Cognitive and Motor Impairment:* Advise patients to not drive a motor vehicle or operate hazardous machinery until they are reasonably certain haloperidol decanoate does not impair their

cognitive and motor functions (5.11).

- *Risk of Encephalopathic Syndrome with Concomitant Use of Lithium:* Monitor closely for early signs of neurological toxicity and discontinue haloperidol decanoate if such signs appear (5.12).
- *Leukopenia, Neutropenia and Agranulocytosis:* Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing haloperidol decanoate if clinically significant decline in WBC occurs in absence of other causative factors. Discontinue haloperidol decanoate in patients with clinically significant neutropenia or an absolute neutrophil count of $<1,000/\text{mm}^3$ (5.13).
- *Hyperprolactinemia:* Elevated prolactin levels may occur during acute and chronic use (5.14).

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 5\%$) were oculogyric crisis and parkinsonism (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- *Drugs that Prolong QTc Interval:* Avoid concomitant use with haloperidol decanoate (7.1).
- See full prescribing information for additional clinically significant drug interactions with haloperidol decanoate (7.2).

USE IN SPECIFIC POPULATIONS

- *Pregnancy:* Neonates exposed to haloperidol decanoate during the third trimester of pregnancy may develop extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and decreased feeding) (8.1).
- *Lactation:* Monitor breastfed infants for excessive sedation, irritability, poor feeding, abnormal muscle movements and tremors (8.2).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 1/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

BOXED WARNING

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage and Administration

2.2 Recommended Supplemental Immediate-release Oral Haloperidol Therapy

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

5.2 Sudden Death, Torsades de Pointes and QTc Interval Prolongation

5.3 Tachycardia and Hypotension

5.4 Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis

5.5 Tardive Dyskinesia

5.6 Neuroleptic Malignant Syndrome

5.7 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

5.8 Seizures

5.9 Hypersensitivity Reactions

5.10 Falls

5.11 Potential for Cognitive and Motor Impairment

- 5.12 Risk of Encephalopathic Syndrome with Concomitant Use of Lithium
- 5.13 Leukopenia, Neutropenia and Agranulocytosis
- 5.14 Hyperprolactinemia
- 5.15 Risk of Severe Neurotoxicity in Patients with Thyrotoxicosis

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Drugs that Prolong the QTc Interval
- 7.2 Other Clinically Significant Drug Interactions

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

BOXED WARNING

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Haloperidol decanoate is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

Haloperidol decanoate is indicated for the treatment of schizophrenia in adults who were previously taking a stable dosage of an immediate-release oral haloperidol product.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage and Administration

Administer haloperidol decanoate by deep intramuscular injection every 4 weeks by a health care professional. **Do not administer haloperidol decanoate intravenously.**

When injecting haloperidol decanoate, use a 21-gauge needle. The maximum volume per injection site is 3 mL.

Table 1 below describes the recommended dosage for haloperidol decanoate injection. The maximum recommended initial dose is 100 mg. If the calculated first recommended dose of haloperidol decanoate is greater than 100 mg, then administer two deep intramuscular injections as follows:

- 100 mg on the first day
- Remainder of the amount 3 days to 7 days later.

Table 1 Haloperidol decanoate Recommended Dosage

Population	First Recommended Dose	Maintenance Dosage ¹
Adult patients less than 65 years old stabilized on ≤ 10 mg of daily immediate-release oral haloperidol with normal hepatic function.	10 times to 15 times previous daily dose of immediate-release oral haloperidol.	10 times to 15 times previous daily dose of immediate-release oral haloperidol administered every 4 weeks. The dosage may be increased by increments of 50 mg or less every 4 weeks until an optimal therapeutic effect is obtained.
Adult patients less than 65 years old stabilized on ≤ 10 mg of daily immediate-release oral haloperidol with hepatic impairment OR Adult patients 65 years and older	10 times to 15 times previous daily dose of immediate-release oral haloperidol. Consider starting at the low end of the dosing range [see <i>Use in Specific Populations</i> (8.5, 8.6) and <i>Clinical Pharmacology</i> (12.3)].	The typical effective dosage range is between 50 mg and 200 mg every 4 weeks.
Adult patients less than 65 years old stabilized on >10 mg of daily immediate-release oral haloperidol	10 times to 20 times previous daily dose of immediate-release oral haloperidol	10 times to 15 times previous daily dose of immediate-release oral haloperidol administered every 4 weeks. The dosage may be increased by increments of 50 mg or less every 4 weeks until an optimal therapeutic effect is obtained.

¹ Clinical experience with haloperidol decanoate at a dosage greater than 450 mg every 4 weeks has been limited.

2.2 Recommended Supplemental Immediate-release Oral Haloperidol Therapy

If schizophrenia symptoms worsen during dosage modification of haloperidol decanoate, consider administering an immediate-release oral haloperidol product in addition to haloperidol decanoate therapy.

3 DOSAGE FORMS AND STRENGTHS

Injection:

- Haloperidol 50 mg/mL (present as haloperidol decanoate) is a clear colorless or pink or yellow amber solution free from particulate matter filled in amber color glass vial.
- Haloperidol 100 mg/mL (present as haloperidol decanoate) is a clear colorless or pink or yellow amber solution free from particulate matter filled in amber color glass vial.

4 CONTRAINDICATIONS

Haloperidol decanoate is contraindicated in patients with:

- Severe toxic central nervous system depression or comatose states from any cause.
- Known hypersensitivity to haloperidol or any components of haloperidol decanoate injection. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with haloperidol [see *Warnings and Precautions* (5.9) and *Adverse Reactions* (6.2)].
- Parkinson's disease [see *Warnings and Precautions* (5.7)].
- Dementia with Lewy bodies [see *Warnings and Precautions* (5.7)].

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In an analysis of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, the risk of death in antipsychotic drug-treated patients was 1.6 times to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the incidence of death in antipsychotic drug-treated patients was about 4.5%, compared to an incidence of about 2.6% in placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

Haloperidol decanoate is not approved for the treatment of patients with dementia-related psychosis [see *Indications and Usage* (1)].

5.2 Sudden Death, Torsades de Pointes and QTc Interval Prolongation

Cases of sudden death, torsades de pointes (TdP) and QTc interval prolongation have been reported in haloperidol-treated patients [see *Adverse Reactions* (6.1, 6.2)]. Cases have been reported even in the absence of predisposing factors. Higher than recommended haloperidol dosages were associated with a higher risk of TdP and QTc interval prolongation.

Avoid use of haloperidol decanoate in patients who are at significant risk of developing TdP including those with congenital long QT syndrome, uncontrolled or significant cardiac disease, recent myocardial infarction, ischemic cardiomyopathy, unstable angina, bradyarrhythmias, uncontrolled hypertension, high degree atrioventricular block, severe aortic stenosis or uncontrolled hypothyroidism. Avoid the concomitant use of haloperidol decanoate with drugs that may increase the risk of the QTc interval prolongation or increase haloperidol exposure. Assess the QTc interval via an ECG at baseline and during treatment as clinically indicated. Obtain serum electrolytes (including potassium, calcium, phosphorus and magnesium) at baseline and during treatment as clinically indicated and correct electrolyte abnormalities.

5.3 Tachycardia and Hypotension

Tachycardia and hypotension (including orthostatic hypotension) have been reported in patients treated with haloperidol [see *Adverse Reactions (6.1)*]. Orthostatic vital signs should be monitored in patients who are at risk for hypotension (e.g., geriatric patients, patients with dehydration, hypovolemia and concomitantly treated with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure or conduction abnormalities) and patients with cerebrovascular disease.

Should hypotension occur and a vasopressor be required, epinephrine must not be used since haloperidol decanoate may block its vasopressor activity and paradoxically lower blood pressure. Instead, metaraminol, phenylephrine or norepinephrine should be used.

5.4 Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis

In placebo-controlled trials, elderly patients with dementia-related psychosis treated with antipsychotics had an increased risk of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack) including fatalities, compared to those treated with placebo.

The mechanism for this increased risk is not known.

Haloperidol decanoate is not approved for the treatment of patients with dementia-related psychosis. Haloperidol decanoate should be used with caution in patients with schizophrenia who have risk factors for cerebrovascular adverse reactions.

5.5 Tardive Dyskinesia

Tardive dyskinesia (TD) may develop in patients treated with antipsychotic drugs, including haloperidol decanoate [see *Adverse Reactions (6.1)*]. TD can develop after a relatively brief treatment period at low dosages and may also occur after discontinuation of treatment. If antipsychotic treatment is discontinued, TD may partially or completely remit. Antipsychotic treatment, however, may suppress or partially suppress the signs and symptoms of TD and may mask the underlying process. The effect that symptomatic suppression has upon the long-term course of TD is unknown.

The TD risk in patients treated with antipsychotic drugs appears to be highest among the elderly, especially elderly women, but it is not possible to predict, which patients are likely to develop TD. The TD risk and the likelihood that TD will become irreversible increase with the duration of antipsychotic drug treatment and the cumulative dosage.

In patients who require chronic antipsychotic treatment, use the lowest dosage and the shortest duration of treatment that produces a satisfactory clinical response. Periodically reassess the need for continued treatment. If signs and symptoms of TD appear in haloperidol decanoate-treated patients, consider drug discontinuation. However, some patients may require haloperidol decanoate treatment despite the presence of TD.

5.6 Neuroleptic Malignant Syndrome

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs [see *Adverse Reactions (6.1)*]. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, delirium and autonomic instability and additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.

If NMS is suspected, immediately discontinue haloperidol decanoate and provide intensive symptomatic treatment and monitoring.

5.7 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

Patients with Parkinson's disease or Dementia with Lewy bodies may experience increased sensitivity to haloperidol. Manifestations of this increased sensitivity include severe extrapyramidal symptoms (e.g., tremor, rigidity, bradykinesia), confusion, sedation and falls. Haloperidol decanoate is contraindicated in patients with Dementia with Lewy bodies and in patients with Parkinson's disease.

5.8 Seizures

Haloperidol decanoate may lower the seizure threshold. Haloperidol decanoate is generally not recommended in patients receiving antiseizure drugs or have a history of seizures or EEG abnormalities. If clinically indicated, maintain patients taking haloperidol decanoate on adequate antiseizure therapy.

5.9 Hypersensitivity Reactions

There have been postmarketing reports of hypersensitivity reactions with haloperidol including anaphylactic reaction, angioedema, dermatitis exfoliative, hypersensitivity vasculitis, rash, urticaria, face edema, laryngeal edema, bronchospasm and laryngospasm [see *Adverse Reactions (6.2)*].

Haloperidol decanoate is contraindicated in patients with known hypersensitivity to haloperidol or any components of haloperidol decanoate.

5.10 Falls

Antipsychotics, including haloperidol decanoate, may cause somnolence orthostatic hypotension, motor instability and sensory abnormality, which may lead to falls and, consequently, fractures and other injuries.

If patients have a condition (or take concomitant drugs) that could exacerbate these effects, complete fall risk assessments when initiating haloperidol decanoate treatment and periodically during long-term treatment.

5.11 Potential for Cognitive and Motor Impairment

Haloperidol decanoate may impair judgement, thinking or motor skills. Inform patients of the risk and advise them to not drive a motor vehicle or operate hazardous machinery until they are reasonably certain that treatment with haloperidol decanoate does not impair their cognitive and motor functions.

5.12 Risk of Encephalopathic Syndrome with Concomitant Use of Lithium

An encephalopathic syndrome, characterized by weakness, lethargy, fever, tremulousness, confusion, extrapyramidal symptoms, leukocytosis and elevated serum enzymes (AST, ALT, GGT, alkaline phosphatase, CK and LDH), BUN and fasting blood sugar, followed by irreversible brain damage has occurred in a few patients treated with concomitant haloperidol and lithium.

Monitor patients who concomitantly use haloperidol decanoate and lithium closely for early signs of neurological toxicity and discontinue haloperidol decanoate or both haloperidol decanoate and lithium promptly if such signs appear.

5.13 Leukopenia, Neutropenia and Agranulocytosis

Leukopenia, neutropenia and agranulocytosis (including fatal cases) have been reported during treatment with antipsychotic drugs, including haloperidol decanoate [*see Adverse Reactions (6.2)*].

Possible risk factors for antipsychotic drug-associated leukopenia and neutropenia include pre-existing low WBC and history of drug-induced leukopenia and neutropenia.

Perform frequent complete blood count (CBC) monitoring during the first few months of haloperidol decanoate therapy in patients with a history of a clinically significant low WBC, drug-induced leukopenia or neutropenia. Consider discontinuing haloperidol decanoate in patients who have a clinically significant decline in their WBC in the absence of other causative factors. Discontinue haloperidol decanoate in patients with clinically significant neutropenia or an absolute neutrophil count of $< 1,000/\text{mm}^3$ and monitor closely until the neutropenia resolves.

5.14 Hyperprolactinemia

Antipsychotic drugs elevate prolactin levels during acute and chronic use and may result in galactorrhea, amenorrhea, gynecomastia and impotence which have been reported with antipsychotic drugs [*see Adverse Reactions (6.1, 6.2) and Use in Specific Populations (8.3)*].

Published epidemiologic studies have shown inconsistent results regarding the potential association between hyperprolactinemia and breast cancer [*see Nonclinical Toxicology (13.1)*].

5.15 Risk of Severe Neurotoxicity in Patients with Thyrotoxicosis

Severe neurotoxicity (rigidity, inability to walk or talk) may occur in patients with thyrotoxicosis who are also receiving antipsychotic drugs, including haloperidol decanoate.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Sudden Death, Torsades de Pointes and QTc Interval Prolongation [see Warnings and Precautions (5.2)]
- Tachycardia and Hypotension [see Warnings and Precautions (5.3)]
- Tardive Dyskinesia [see Warnings and Precautions (5.5)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.6)]
- Seizures [see Warnings and Precautions (5.8)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.9)]
- Leukopenia, Neutropenia and Agranulocytosis [see Warnings and Precautions (5.13)]
- Hyperprolactinemia [see Warnings and Precautions (5.14)]
- Risk of Severe Neurotoxicity in Patients with Thyrotoxicosis [see Warnings and Precautions (5.15)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions Identified in Clinical Trials with Haloperidol Decanoate

The data described below reflect exposure to 15 mg to 500 mg (1.7 times the maximum recommended dosage) of haloperidol decanoate monthly in 13 clinical trials of

410 adult patients with schizophrenia or an unapproved condition. These clinical trials comprised of:

- 1 double-blind, active comparator-controlled trial with fluphenazine decanoate (Trial 1).
- 2 trials comparing haloperidol decanoate to oral haloperidol (Trials 2 and 3).
- 9 open-label trials.
- 1 dose-response trial.

The most common adverse reactions that occurred in $\geq 5\%$ of haloperidol decanoate-treated patients in Trial 1 were Parkinsonism and oculogyric crisis.

Adverse reactions that occurred in $\geq 1\%$ of haloperidol decanoate-treated patients in Trial 1 are shown in Table 2. Trial 1 was not designed to evaluate meaningful comparisons of the incidence of adverse reactions in the haloperidol decanoate and fluphenazine decanoate treatment groups.

Table 2 Adverse Reactions that Occurred in $\geq 1\%$ of Haloperidol decanoate-treated Patients and Fluphenazine Decanoate-treated Patients in Trial 1^a

	Haloperidol decanoate (n=36)	Fluphenazine decanoate (n=36)
Extrapyramidal disorder:		
Parkinsonism	31%	44%
Oculogyric crisis	6%	0%

Akinesia	3%	22%
Akathisia	3%	14%
Tremor	3%	0%
Abdominal pain	3%	0%
Headache	3%	0%

^a The study was not designed to evaluate meaningful comparisons of the incidence of adverse reactions in the haloperidol decanoate and the fluphenazine decanoate treatment groups.

Less common adverse reactions (<1%) that occurred in Trial 1 and other adverse reactions that occurred in Trials 2 and 3 and open-label and dose-response clinical trials of haloperidol decanoate are listed below.

- *Cardiac Disorders:* Tachycardia
- *Endocrine Disorders:* Hyperprolactinemia
- *Eye Disorders:* Vision blurred
- *Gastrointestinal Disorders:* Constipation, Dry mouth, Salivary hypersecretion
- *General Disorders and Administration Site Conditions:* Weight increased, Injection site reaction
- *Musculoskeletal and Connective Tissue Disorders:* Muscle rigidity
- *Nervous System Disorders:* Dyskinesia, Dystonia, Cogwheel rigidity, Hypertonia, Masked facies, Sedation, Somnolence
- *Reproductive System Disorders:* Erectile dysfunction

Adverse Reactions Identified in Clinical Trials with Immediate-Release Haloperidol Products

Based on clinical trials with immediate-release haloperidol products that included 1,579 patients, the following adverse reactions were reported:

- *Musculoskeletal and Connective Tissue Disorders:* Torticollis, Trismus, Muscle twitching
- *Nervous System Disorders:* Neuroleptic malignant syndrome, Tardive dyskinesia, Bradykinesia, Hyperkinesia, Hypokinesia, Dizziness, Nystagmus
- *Psychiatric Disorders:* Loss of libido, Restlessness
- *Reproductive System and Breast Disorders:* Amenorrhea, Galactorrhea, Dysmenorrhea, Menorrhagia, Breast discomfort
- *Skin and Subcutaneous Tissue Disorders:* Acneiform skin reactions
- *Vascular Disorders:* Hypotension, Orthostatic hypotension

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of haloperidol, including haloperidol decanoate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- *Blood and Lymphatic System Disorders:* Pancytopenia, Agranulocytosis, Thrombocytopenia, Leukopenia, Neutropenia
- *Cardiac Disorders:* Ventricular fibrillation, Torsade de pointes, Ventricular tachycardia, Extrasystoles, QTc interval prolongation
- *Endocrine Disorders:* Inappropriate antidiuretic hormone secretion
- *Gastrointestinal Disorders:* Vomiting, Nausea
- *General Disorders and Administration Site Conditions:* Sudden death, Face edema,

- Edema, Hyperthermia, Hypothermia, Injection site abscess, Weight decreased
- *Hepatobiliary Disorders*: Acute hepatic failure, Hepatitis, Cholestasis, Jaundice, Liver function test abnormal
 - *Immune System Disorders*: Anaphylactic reaction, Hypersensitivity
 - *Metabolic and Nutritional Disorders*: Hypoglycemia
 - *Musculoskeletal and Connective Tissue Disorders*: Rhabdomyolysis
 - *Nervous System Disorders*: Convulsion, Opisthotonus, Tardive dystonia
 - *Pregnancy, Puerperium and Perinatal Conditions*: Neonatal drug withdrawal syndrome
 - *Psychiatric Disorders*: Agitation, Confusional state, Depression, Insomnia
 - *Renal and Urinary Disorders*: Urinary retention
 - *Reproductive System and Breast Disorders*: Priapism, Gynecomastia
 - *Respiratory, Thoracic and Mediastinal Disorders*: Laryngeal edema, Bronchospasm, Laryngospasm, Dyspnea
 - *Skin and Subcutaneous Tissue Disorders*: Angioedema, Dermatitis exfoliative, Hypersensitivity vasculitis, Photosensitivity reaction, Urticaria, Pruritus, Rash, Hyperhidrosis

7 DRUG INTERACTIONS

7.1 Drugs that Prolong the QTc Interval

Avoid concomitant use of haloperidol decanoate with other drugs with a known potential to prolong the QTc interval. If concomitant use cannot be avoided [see *Warnings and Precautions* (5.2)]:

- Obtain ECGs when initiating and during concomitant use as clinically indicated.
- Obtain serum electrolytes (including potassium, calcium, phosphorus and magnesium) when initiating and during concomitant use as clinically indicated.

QTc interval prolongation has been observed with haloperidol decanoate treatment. Concomitant use of haloperidol decanoate with other products that prolong the QTc interval may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including torsade de pointes, other serious arrhythmias and sudden death [see *Warnings and Precautions* (5.2)].

7.2 Other Clinically Significant Drug Interactions

Table 3 describes other clinically significant drug interactions of haloperidol decanoate.

Table 3 Other Clinically Significant Drugs Interactions¹

CNS Depressants	
Clinical Impact	Haloperidol may potentiate CNS depressants.
Prevention or Management	Avoid concomitant use of haloperidol decanoate with CNS depressants such as anesthetics, opioids and alcohol.
CYP3A4 and/or CYP2D6 Inhibitors	
Clinical Impact	CYP3A4 and/or CYP2D6 inhibitors increase haloperidol exposure (haloperidol is a CYP3A4 and CYP2D6 substrate) [see <i>Clinical Pharmacology</i> (12.3)]. Concomitant use of haloperidol decanoate and CYP3A4 and/or CYP2D6 inhibitors may increase the risk of haloperidol-

	associated adverse reactions.
Prevention or Management	Monitor for signs or symptoms of increased or prolonged pharmacologic effects of haloperidol. Decrease the dosage of haloperidol decanoate as clinically necessary.
CYP3A4 Inducers	
Clinical Impact	CYP3A4 inducers decrease haloperidol exposure (haloperidol is a CYP3A4 substrate) [see <i>Clinical Pharmacology (12.3)</i>]. Concomitant use of haloperidol decanoate with CYP3A4 inducers may reduce the effectiveness of haloperidol decanoate.
Prevention or Management	Monitor patients and if necessary, increase the dosage of haloperidol decanoate.
CYP2D6 Substrates	
Clinical Impact	Haloperidol is a CYP2D6 inhibitor. Plasma concentrations of CYP2D6 substrates may increase when they are concomitantly administered with haloperidol decanoate.
Prevention or Management	Monitor plasma concentrations of the CYP2D6 substrate, if possible. Consider reducing the dosage of the CYP2D6 substrate, if necessary. Refer to the Prescribing Information of the CYP2D6 substrate.
Dopaminergic Drugs	
Clinical Impact	Haloperidol may antagonize the effects of levodopa, dopamine agonists and other drugs intended to increase dopamine levels.
Prevention or Management	haloperidol decanoate is contraindicated in patients with Parkinson's disease and dementia with Lewy bodies. For conditions other than Parkinson's disease and dementia with Lewy bodies, when possible, avoid concomitant use of haloperidol decanoate with dopaminergic drugs [see <i>Warnings and Precautions (5.7)</i>] .
Anticholinergic Drugs	
Clinical Impact	The healthcare provider should keep in mind the possible increase in intraocular pressure when anticholinergic drugs are administered concomitantly with haloperidol decanoate.
Prevention or Management	Monitor and manage patients as clinically appropriate.
Lithium	
Clinical Impact	Concomitant use of haloperidol decanoate with lithium may cause an encephalopathic syndrome followed by irreversible brain damage [see <i>Warnings and Precautions (5.12)</i>] .
Prevention or Management	Monitor patients who concomitantly use haloperidol decanoate with lithium closely for early signs of neurological toxicity and discontinue haloperidol decanoate or both haloperidol decanoate and lithium promptly if such signs appear.

¹ See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 and/or CYP2D6 inhibitors, CYP3A4 inducers and CYP2D6 substrates.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from published epidemiologic studies of pregnant patients exposed to haloperidol have not established a drug-associated risk of major birth defects or miscarriage. Case reports of limb malformations in neonates have been reported in haloperidol-treated mothers; however, causal relationships were not established in these cases. There are risks to the pregnant patient from untreated schizophrenia, including increased risk of relapse, hospitalization and suicide (see *Clinical Considerations*).

Haloperidol decanoate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and decreased feeding) following delivery (see *Clinical Considerations*).

The estimated background risk of major birth defects and miscarriage in patients with schizophrenia is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo/Fetal Risk: There is risk to the pregnant patient from untreated schizophrenia, including increased risk of schizophrenia relapse, hospitalization and suicide. Schizophrenia is associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.

Fetal/Neonatal Adverse Reactions: Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and decreased feeding have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. Transient neonatal dyskinesia has also been reported. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal, withdrawal and dyskinesia symptoms and manage symptoms appropriately.

Data

Animal Data

Rats or rabbits administered oral haloperidol at doses of 0.5 to 7.5 mg/kg (approximately

0.2 to 7 times the maximum recommended human oral dose (MRHD) of 20 mg/day based on mg/m² body surface area) showed an increase in incidence of resorption, reduced fertility, delayed delivery and pup mortality. No fetal abnormalities were observed at these doses in rats or rabbits. Cleft palate has been observed in mice administered oral haloperidol at a dose of 0.5 mg/kg, which is approximately 0.1 times the oral MRHD based on mg/m² body surface area.

8.2 Lactation

Risk Summary

Literature reports suggest that haloperidol is detected in human milk of haloperidol-treated mothers with a relative infant dose ranging from 2% to 12%. Haloperidol has also been detected in the plasma and urine of breastfed infants. There has been a report of lethargy, poor feeding and slowing of motor movements in an infant exposed to haloperidol through human milk. Haloperidol may increase prolactin levels in some patients which can lead to galactorrhea.

Monitor infants exposed to haloperidol decanoate via human milk for excessive sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements).

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for haloperidol decanoate and any potential adverse effects on the breastfed child from haloperidol decanoate or from the mother's underlying condition.

8.3 Females and Males of Reproductive Potential

Infertility

Females: Based on the pharmacologic action of haloperidol (D2 receptor antagonism), treatment with haloperidol decanoate may result in an increase in serum prolactin levels, which may lead to a reduction in fertility in females of reproductive potential.

Males: Based on animal studies, male fertility may be impaired by treatment with haloperidol [see *Nonclinical Toxicology* (13.1)].

8.4 Pediatric Use

Safety and effectiveness of haloperidol decanoate have not been established in pediatric patients.

8.5 Geriatric Use

Clinical studies of haloperidol decanoate did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

The exposure of haloperidol may be higher in geriatric patients compared to young adult patients. Results from small clinical studies suggest a lower clearance and a longer elimination half-life of haloperidol in geriatric patients [see *Clinical Pharmacology* (12.3)]. Consider starting at the low end of the recommended dosing range for the first haloperidol decanoate dose in geriatric patients [see *Dosage and Administration* (2.1)].

Antipsychotic drugs increase the risk of death in elderly patients with dementia-related psychosis. Haloperidol decanoate is not approved for the treatment of patients with dementia-related psychosis [see *Warnings and Precautions* (5.1)].

Elderly patients with dementia-related psychosis treated with antipsychotics had an

increased risk of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack) including fatalities, compared to those treated with placebo [*see Warnings and Precautions (5.4)*].

Antipsychotic drugs increase the risk of tardive dyskinesia and this risk appears to be highest among the elderly, particularly elderly women [*see Warnings and Precautions (5.5)*].

8.6 Hepatic Impairment

Haloperidol is extensively metabolized in the liver, therefore, haloperidol concentrations may be higher in patients with hepatic impairment compared to patients with normal hepatic function. In patients with hepatic impairment, consider starting at the low end of the recommended dosing range for the first haloperidol decanoate dose [*see Dosage and Administration (2.1)*].

10 OVERDOSAGE

Reported overdose signs and symptoms are those resulting from an exaggeration of the drug's known pharmacologic effects (e.g., drowsiness and sedation, tachycardia and hypotension) and adverse reactions, the most prominent of which would be: 1) severe extrapyramidal symptoms, 2) hypotension or 3) sedation. Patients may appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state. Extrapyramidal reactions may be manifested by muscular weakness or rigidity and a generalized or localized tremor, as demonstrated by the akinetic or agitans types, respectively. The risk of QTc interval prolongation and torsade de pointes should be considered [*see Adverse Reactions (6.2)*].

Management of Overdose

There is no specific antidote for a haloperidol overdose.


- Should hypotension occur and a vasopressor be required, epinephrine must not be used since haloperidol decanoate may block its vasopressor activity and paradoxical further lowering of the blood pressure may occur. Instead, metaraminol, phenylephrine or norepinephrine should be used.
- In case of severe extrapyramidal reactions, antiparkinson drugs should be administered and should be continued for several weeks and then withdrawn gradually as extrapyramidal symptoms may emerge if discontinued abruptly.
- Monitor ECG and vital signs for signs of QTc interval prolongation or dysrhythmias and continue monitoring until the dysrhythmias resolve and the haloperidol-induced QTc interval prolongation resolves.
- Dialysis is not recommended in the treatment of overdose because it removes only very small amounts of haloperidol.

Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

Haloperidol decanoate, USP is the decanoate ester of the butyrophenone, haloperidol. It has a markedly extended duration of effect. It is available in sesame oil in sterile form for

intramuscular (IM) injection. The structural formula of haloperidol decanoate, 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4 piperidiny decanoate, is:



The molecular formula is C₃₁H₄₁ClFNO₃ and has a molecular weight of 530.12.

Haloperidol decanoate, USP is almost insoluble in water (0.01 mg/mL), but is soluble in most organic solvents.

Each mL of Haloperidol decanoate injection, 50 mg/mL for IM injection contains 50 mg haloperidol (present as haloperidol decanoate, USP 70.52 mg) in a sesame oil vehicle, with 1.2% (w/v) benzyl alcohol as a preservative.

Each mL of Haloperidol decanoate injection, 100 mg/mL for IM injection contains 100 mg haloperidol (present as haloperidol decanoate, USP 141.04 mg) in a sesame oil vehicle, with 1.2% (w/v) benzyl alcohol as a preservative.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of haloperidol decanoate for the treatment of schizophrenia in adults is unclear. However, its effect in schizophrenia could be mediated through its activity as an antagonist at central dopamine type 2 receptors. Haloperidol also binds to alpha-1 adrenergic receptors, but with lower affinity and displays minimal binding to muscarinic cholinergic and histaminergic (H₁) receptors.

12.2 Pharmacodynamics

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of haloperidol have not been fully characterized.

12.3 Pharmacokinetics

Absorption

The plasma concentrations of haloperidol gradually rise, reaching a peak at about 6 days after the haloperidol decanoate injection and fall thereafter, with an apparent half-life of about 3 weeks. Steady state plasma concentrations of haloperidol are achieved within 2

to 4 months in patients receiving monthly haloperidol decanoate injections.

The relationship between the haloperidol decanoate dosage and plasma haloperidol concentration is roughly linear for dosages below 450 mg (1.5 times the maximum recommended dosage [see *Dosage and Administration* (2.1)]); however, the pharmacokinetics of haloperidol following intramuscular injections can be quite variable between patients.

Elimination

Metabolism: Haloperidol is metabolized by several routes. The major pathways are glucuronidation and ketone reduction. The cytochrome P450 enzyme system is also involved, particularly CYP3A4 and, to a lesser extent, CYP2D6.

Excretion:

Less than 3% of administered haloperidol is eliminated unchanged in the urine. The apparent half-life of haloperidol following intramuscular injection of haloperidol decanoate is about 3 weeks.

Specific Populations

Patients with Hepatic Impairment

Studies in patients with hepatic impairment have not been conducted. Haloperidol is extensively metabolized in the liver, therefore, haloperidol concentrations may be higher in patients with hepatic impairment compared to patients with normal hepatic function [see *Use in Specific Populations* (8.6)].

Geriatric Patients

Haloperidol plasma concentrations in geriatric patients were higher than in younger adult patients when administered the same dosage. Results from small clinical studies suggest a lower clearance and a longer elimination half-life of haloperidol in geriatric patients. The results are within the observed variability in haloperidol pharmacokinetics [see *Use in Specific Populations* (8.5)].

Patients with Renal Impairment

Studies in patients with renal impairment have not been conducted.

Drug Interaction Studies

Ketoconazole and Paroxetine

The haloperidol plasma concentrations increased when ketoconazole (400 mg/day, strong CYP3A4 inhibitor) and paroxetine (20 mg/day, strong CYP2D6 inhibitor) were concomitantly administered with haloperidol [see *Drug Interactions* (7.2)].

Valproate: Sodium valproate, a drug known to inhibit glucuronidation, does not affect haloperidol plasma concentrations.

Rifampin: In a study with 12 patients with schizophrenia, concomitant administration of oral haloperidol and rifampin, a strong CYP3A4 inducer, resulted in decreased plasma haloperidol concentrations by a mean of 70% and increased mean scores on the Brief

Psychiatric Rating Scale from baseline. In five other patients with schizophrenia treated with oral haloperidol and rifampin, discontinuation of rifampin resulted in a mean 3.3-fold increase in haloperidol concentrations [see *Drug Interactions (7.2)*].

Carbamazepine: In a study with 11 patients with schizophrenia, concomitant administration of haloperidol and increasing doses of carbamazepine, a CYP3A4 strong inducer, resulted in decreased haloperidol plasma concentrations in a linear manner with increasing carbamazepine concentrations [see *Drug Interactions (7.2)*].

Effect of Haloperidol on Other Drugs

Haloperidol is an inhibitor of CYP2D6. Plasma concentrations of CYP2D6 substrates may increase when they are concomitantly administered with haloperidol [see *Drug Interactions (7.2)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility

Carcinogenesis

Carcinogenicity studies using oral haloperidol were conducted in Wistar rats (dosed at up to 5 mg/kg daily for 24 months) and in Albino Swiss mice (dosed at up to 5 mg/kg daily for 18 months).

- In the rat study, survival was reduced in all haloperidol dose groups, decreasing the number of rats at risk for developing tumors. However, a relatively greater number of rats survived to the end of the study in the high dose haloperidol male and female groups. These haloperidol-treated rats at doses up to approximately 2.5 times the maximum recommended human oral dose (MRHD) of haloperidol of 20 mg/day based on mg/m²body surface area did not have a greater incidence of tumors than control-treated rats.
- In female mice, there was a statistically significant increase in mammary gland neoplasia and total tumor incidence at haloperidol doses approximately 0.3 and 1.2 times the oral MRHD based on mg/m²body surface area and there was statistically significant increase in pituitary gland neoplasia at approximately 1.2 times the oral MRHD. In male mice, no statistically significant differences in incidences of total tumors or specific tumor types were noted.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent *in vitro*, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs [see *Warnings and Precautions (5.14)*].

Mutagenesis

No mutagenic potential of haloperidol decanoate was found in the Ames Salmonella assay. Negative or inconsistent positive findings have been obtained in *in vitro* and *in vivo* studies of effects of haloperidol on chromosome structure and number. The available cytogenetic evidence is considered too inconsistent to be conclusive.

Impairment of Fertility

Haloperidol was orally administered to male rats at doses of 0.5 mg/kg/day, 2.5 mg/kg/day and 15 mg/kg/day (approximately 0.2 to 7 times the oral MRHD based on mg/m² body surface area) for 63 days prior to mating with untreated females. Decreases in mating performance and fertility, as well as markedly decreased motor activity, was observed at seven times the oral MRHD based on mg/m² body surface area. The NOAEL of 2.5 mg/kg/day is approximately equal to the oral MRHD based on mg/m² body surface area.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

Haloperidol decanoate injection, 50 mg haloperidol as 70.52 mg per mL haloperidol decanoate is a clear colorless or pink or yellow amber solution supplied as:

NDC Number	Strength	Pack styleCode	Description
70710-1461-9	50 mg/mL*	3 vials per carton	1 mL Single-Dose, Flip-top Vial
70710-1461-6	50 mg/mL*	10 vials per carton	1 mL Single-Dose, Flip-top Vial
70710-1462-1	250 mg/5 mL* (50 mg/mL)	1 vial per carton	5 mL Multiple-Dose, Flip-top Vial
70710-1462-5	250 mg/5 mL* (50 mg/mL)	5 vials per carton	5 mL Multiple-Dose, Flip-top Vial

*as haloperidol.

Haloperidol decanoate injection, 100 mg haloperidol as 141.04 mg per mL haloperidol decanoate is a clear colorless or pink or yellow amber solution supplied as:

NDC Number	Strength	Pack styleCode	Description
70710-1463-1	100 mg/mL*	1 vial per carton	1 mL Single-Dose, Flip-top Vial
70710-1463-5	100 mg/mL*	5 vials per carton	1 mL Single-Dose, Flip-top Vial
70710-1464-1	500 mg/5 mL* (100 mg/mL)	1 vial per carton	5 mL Multiple-Dose, Flip-top Vial
70710-1464-5	500 mg/5 mL* (100 mg/mL)	5 vials per carton	5 mL Multiple-Dose, Flip-top Vial

*as haloperidol.

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. Protect from light. Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

Sudden Death, Torsades de Pointes and QTc Interval Prolongation

Inform patients that there have been reports of sudden death, torsades de Pointes and QTc interval prolongation in haloperidol-treated patients. Advise patients or caregivers to

seek immediate medical attention if they suspect or develop signs or symptoms associated with the clinical consequences of QTc interval prolongation [see *Warnings and Precautions* (5.2)].

Tardive Dyskinesia

Inform patients that tardive dyskinesia (TD) may develop with haloperidol decanoate. Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur [see *Warnings and Precautions* (5.5)].

Neuroleptic Malignant Syndrome

Counsel patients about a potentially fatal adverse reaction, Neuroleptic Malignant Syndrome (NMS), that has been reported with administration of antipsychotic drugs. Advise patients, family members or caregivers to contact the health care provider or to report to the emergency room if they experience signs and symptoms of NMS [see *Warnings and Precautions* (5.6)].

Hypersensitivity Reactions

Inform patients of the potential risk of hypersensitivity reactions. Advise patients to stop taking haloperidol decanoate and seek immediate attention if signs or symptoms of a hypersensitivity reaction occur [see *Warnings and Precautions* (5.9)].

Falls

Inform patients that haloperidol decanoate can cause somnolence, orthostatic hypotension, motor instability and sensory abnormality that may lead to falls. Advise patients to notify their healthcare provider if any of these symptoms occur [see *Warnings and Precautions* (5.10)].

Potential for Cognitive and Motor Impairment

Inform patients of the risk and advise them to not drive a motor vehicle or operate hazardous machinery until they are reasonably certain that treatment with haloperidol decanoate does not impair their cognitive and motor functions [see *Warnings and Precautions* (5.11)].

Leukopenia/Neutropenia

Advise patients with a pre-existing low WBC or a history of drug induced leukopenia or neutropenia that they should have their CBC monitored while taking haloperidol decanoate [see *Warnings and Precautions* (5.13)].

Hyperprolactinemia

Counsel patients on signs and symptoms of hyperprolactinemia that may be associated with chronic use of haloperidol decanoate. Advise the patients to seek medical attention if they experience any of the following: amenorrhea, galactorrhea, erectile dysfunction or gynecomastia [see *Warnings and Precautions* (5.14)].

Pregnancy

Advise pregnant patients to notify their health care provider if they become pregnant or intend to become pregnant during treatment with haloperidol decanoate. Advise patients

that haloperidol decanoate exposure during the third trimester of pregnancy may cause adverse effects in the neonate, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and decreased feeding [*see Use in Specific Populations (8.1)*].

Lactation

Advise breastfeeding patients using haloperidol decanoate to monitor infants for excess sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements) and to seek medical care if they notice these signs [*see Use in Specific Populations (8.2)*].

Infertility

Advise females and males of reproductive potential that haloperidol decanoate may impair fertility due to an increase in serum prolactin levels [*see Use in Specific Populations (8.3)*].

Drug Interactions

Advise patients to inform their health care provider before starting or discontinuing a prescription drug, nonprescription drug or supplement [*see Warnings and Precautions (5.2) and Drug Interactions (7)*].

Please address medical inquiries to MedicalAffairs@zydususa.com or Tel.: 1-877-993-8779.

SPL UNCLASSIFIED

Manufactured by:

Zydus Lifesciences Ltd.

Vadodara, India.

Distributed by:

Zydus Pharmaceuticals (USA) Inc.

Pennington, NJ 08534

Rev.:01/26

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70710-1461-1

Haloperidol Decanoate Injection

50 mg/mL*

For Intramuscular Use Only

1 mL Single-Dose Vial

Sterile

Rx only

zydus pharmaceuticals



(01)00370710146115

NDC 70710-1461-1

**Haloperidol
Decanoate Injection**

50 mg/mL*

For Intramuscular Use Only
1 mL Single-Dose Vial

zydus

Sterile
Rx only

*Each mL contains 50 mg haloperidol.
Store at 20°C to 25°C (68°F to 77°F)
[see USP Controlled Room Temperature].
Do not refrigerate or freeze.
PROTECT FROM LIGHT

Product of Italy
Distributed by: Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534

GUJ/DRUGS/G/28/1609

XXXXXX
Made In India
Rev.: 12/22

Lot: _____
Exp: _____

NDC 70710-1462-1

Haloperidol

Decanoate Injection 250 mg/5 mL*

(50 mg/mL)

For Intramuscular Use Only

5 mL Multiple-Dose Vial

Sterile

Rx only

zydus pharmaceuticals



(01)00370710146214

NDC 70710-1462-1

**Haloperidol
Decanoate Injection**

250 mg/5 mL*
(50 mg/mL)

For Intramuscular Use Only
5 mL Multiple-Dose Vial

zydus

Sterile
Rx only

*Each mL contains 50 mg haloperidol as 70.52 mg haloperidol decanoate
in a sesame oil vehicle, with 1.2 % (w/v) benzyl alcohol as a preservative.
Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
Do not refrigerate or freeze. **PROTECT FROM LIGHT**

Usual Dosage: See package insert for full prescribing information.
Retain in carton until contents are used.

Distributed by: Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534

Product of Italy
Made In India
GUJ/DRUGS/G/28/1609

XXXXXX
Rev.: 12/22

Lot: _____
Exp: _____

NDC 70710-1463-1

Haloperidol Decanoate Injection

100 mg/mL*

For Intramuscular Use Only

1 mL Single-Dose Vial

Sterile

Rx only

zydus pharmaceuticals

(01)00370710146313

NDC 70710-1463-1

**Haloperidol
Decanoate Injection**

100 mg/mL*

For Intramuscular Use Only

1 mL Single-Dose Vial

zydus

Sterile
Rx only

*Each mL contains 100 mg haloperidol.
Store at 20°C to 25°C (68°F to 77°F)
[see USP Controlled Room Temperature].
Do not refrigerate or freeze.
PROTECT FROM LIGHT

Product of Italy
Distributed by: Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534

GUJ/DRUGS/G/28/1609

xxxxxx
Made In India
Rev: 12/22

Lot:

Exp:

NDC 70710-1464-1

Haloperidol

Decanoate Injection

500 mg/5 mL*

(100 mg/mL)

For Intramuscular Use Only

5 mL Multiple-Dose Vial

Sterile

Rx only

zydus pharmaceuticals



(01)00370710146412

NDC 70710-1464-1

Haloperidol Decanoate Injection

500 mg/5 mL*
(100 mg/mL)

For Intramuscular Use Only
5 mL Multiple-Dose Vial



**Sterile
Rx only**

*Each mL contains 100 mg haloperidol as 141.04 mg haloperidol decanoate in a sesame oil vehicle, with 1.2 % (w/v) benzyl alcohol as a preservative. Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze. **PROTECT FROM LIGHT**

Usual Dosage: See package insert for full prescribing information. Retain in carton until contents are used.

Distributed by: Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534

Product of Italy
GUJ/DRUGS/G/28/1609

XXXXXX
Rev: 12/22

HALOPERIDOL DECANOATE

haloperidol decanoate injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70710-1461
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HALOPERIDOL DECANOATE (UNII: AC20PJ4101) (HALOPERIDOL - UNII:J6292F8L3D)	HALOPERIDOL	50 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
SESAME OIL (UNII: QX10HYY4QV)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70710-1461-6	10 in 1 CARTON	11/14/2019	
1		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		
2	NDC:70710-1461-9	3 in 1 CARTON	11/14/2019	
2		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA211180	11/14/2019	

HALOPERIDOL DECANOATE

haloperidol decanoate injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70710-1462
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HALOPERIDOL DECANOATE (UNII: AC20PJ4101) (HALOPERIDOL - UNII:J6292F8L3D)	HALOPERIDOL	50 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
SESAME OIL (UNII: QX10HYY4QV)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70710-1462-1	1 in 1 CARTON	11/14/2019	
1		5 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product		
2	NDC:70710-1462-5	5 in 1 CARTON	11/14/2019	
2		5 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA211180	11/14/2019	

HALOPERIDOL DECANOATE

haloperidol decanoate injection

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70710-1463
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
HALOPERIDOL DECANOATE (UNII: AC20PJ4101) (HALOPERIDOL - UNII:J6292F8L3D)	HALOPERIDOL	100 mg in 1 mL

Inactive Ingredients	
Ingredient Name	Strength
SESAME OIL (UNII: QX10HYY4QV)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70710-1463-1	1 in 1 CARTON	11/14/2019	
1		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		
2	NDC:70710-1463-5	5 in 1 CARTON	11/14/2019	
2		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA211180	11/14/2019	

HALOPERIDOL DECANOATE

haloperidol decanoate injection

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70710-1464
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety		

Ingredient Name		Basis of Strength	Strength	
HALOPERIDOL DECANOATE (UNII: AC20PJ4101) (HALOPERIDOL - UNII:J6292F8L3D)		HALOPERIDOL	100 mg in 1 mL	
Inactive Ingredients				
Ingredient Name		Strength		
SESAME OIL (UNII: QX10HYY4QV)				
BENZYL ALCOHOL (UNII: LKG8494WBH)				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70710-1464-1	1 in 1 CARTON	11/14/2019	
1		5 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product		
2	NDC:70710-1464-5	5 in 1 CARTON	11/14/2019	
2		5 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA		ANDA211180	11/14/2019	

Labeler - Zydus Pharmaceuticals USA Inc. (156861945)

Registrant - Zydus Pharmaceuticals USA Inc. (156861945)

Establishment

Name	Address	ID/FEI	Business Operations
Zydus Lifesciences Limited		873671928	ANALYSIS(70710-1461, 70710-1462, 70710-1463, 70710-1464) , MANUFACTURE(70710-1461, 70710-1462, 70710-1463, 70710-1464)

Revised: 1/2026

Zydus Pharmaceuticals USA Inc.